MedTrace Logo

Mesalazine Therapy in Patients With Irritable Bowel Syndrome

NCT00626288 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2013-07-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether Mesalazine is effective in the treatment of the abdominal discomfort or pain of Irritable Bowel Syndrome patients.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

Mesalazine

Mesalazine 800mg t.i.d. 12 weeks

DRUG

Placebo

Placebo cpr, t.i.d. 12 weeks

Sponsors & Collaborators

  • SOFAR S.p.A.

    lead INDUSTRY

Principal Investigators

  • Roberto Corinaldesi, Professor · Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola Malpighi

  • Barbara Giovanni, Doctor · Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola Malpighi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2012-03-31
Completion
2012-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00626288 on ClinicalTrials.gov